Pfizer

INFLECTRA

Manufacturer:

Pfizer

Inflectra HCPCS:

Q5103

HCPCS Code Descriptor:

Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg

Category:

Q Code

Inflectra NDCs:

00069-0809-01

Primary Type:

Immunology Anti-TNF Biosimilar

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Inflectra:

INFLECTRA is an Immunology Anti-TNF Biosimilar drug manufactured by Pfizer and administered via the Intravenous route of administration. The Q Code: Q5103 is aligned to the drug INFLECTRA.

Inflectra (infliximab) is a monoclonal antibody and is used to treat a range of inflammatory autoimmune disorders. Inflectra binds to tumor necrosis factor-alpha and prevents it from activating certain processes. This drug is administered via a 2-hour intravenous infusion. Inflectra is manufactured by Pfizer and is a biosimilar to Remicade (J1745). Inflectra was aligned to the Q Code: Q5102 until March 2018, when it was realigned to the Q Code: Q5103. Patient Assistance can be found through the Pfizer EnCompass program.

ACCESS PRICING AND MORE BY REGISTERING

Q5103 Added Date:

April 1, 2018

Q5103 Effective Date:

April 1, 2018

Q5103 Termination Date:

HCPCS Active

Inflectra billing and coding information can be found through Pfizer at the link below:
Inflectra patient assistance information can be found through Pfizer enCompass at the URL: https://www.pfizerencompass.com/
INFLECTRA prescribing information can be found at the link below:
Information regarding INFLECTRA’s side effects can be found at MedlinePlus